Citations

Clear

2303 citation(s) found for "Yu, Edward".

Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate
Hall, William A. , Fishbane, Nick , Xu, Melody, Davicioni, Elai , Den, Robert B. , Dess, Robert T. , Wong, Anthony , Schaeffer, Edward M. , Karnes, R. Jeffrey , Kim, Hyung L. , Klein, Eric A. , Davis, John W. , Ross, Ashley E. , Tosoian, Jeffrey J. , Mehra, Rohit , Salami, Simpa S. , Nguyen, Paul L. , Lawton, C.A., Spratt, Daniel E. , Feng, Felix Y. , Xu, Melody J , Davicioni, Elai , Den, Robert B , Dess, Robert T , Jackson, William C , Wong, Anthony C , Carroll, Peter R , Bismar, Tarek A , Kim, Hyung L , Klein, Eric A , Tosoian, Jeffrey J , Morgan, Todd M , Salami, Simpa S , Spratt, Daniel E , Liu, Yang , Mahal, Brandon A. , Jackson, Will , Cooperberg, Matthew R , Morgan, Todd M.

Mayo Clinic

JCO Precision Oncology | October 16, 2020 | Volume: No volume available | Issue: 4 | Pages: 1228-1238

10.1200/po.20.00013 | PMID 35050780 Get It

PURPOSE Pretreatment estimates of seminal vesicle invasion (SVI) are challenging and significantly influence the management of prostate cancer. We sought to improve current models to predict SVI through the development of an SVI prediction genomic signature. PATIENTS AND METHODS A total of 15,889 patients who underwent radical prostatectomy (RP) with available baseline clinical, pathology, and transcriptome data were retrieved from the GRID registry (ClinicalTrials.gov identifier: NCT02609269 ) and other retrospective cohorts. These data were divided into a training (n = 6,766), test (n = 3,363), and two validation (n = 5,062 and 698) cohorts. Multivariable logistic regression was performed to assess the predictive effect of the genomic SVI (gSVI) classifier in the presence of established nomograms (Partin Tables and Memorial Sloan Kettering Cancer Center [MSKCC]). RESULTS In the training cohort, univariable filtering identified 2,132 genes that were differentially expressed between RP tumors with and without SVI. Model parameters were tuned to maximize the area under the curve (AUC) in the testing cohort, resulting in a logistic generalized linear model with 581 genes. The gSVI model scores range from 0 to 1. In the first validation set, gSVI showed superior discrimination of patients with and without SVI at RP compared with other prognostic signatures trained to predict distant metastasis or clinical recurrence. Of the 698 patients in the second validation set, gSVI combined with the MSKCC nomogram had a superior AUC (0.86) compared with either nomogram individually (0.81). CONCLUSION The gSVI represents a novel and validated expression signature to predict the presence of SVI before treatment with surgery. This genomic tool adds discriminatory power to existing clinical predictive nomograms and may help with pretreatment counseling and decision making.
Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, Minnesota
Bakhshi, Zeinab , Yadav, Siddhant, Salonen, Bradley R. , Bonnes, Sara L. , Varayil, Jithinraj Edakkanambeth , Harmsen, William S. , Tremaine, William J., Loftus, Edward V. , Harmsen, William Scott, Hurt, Ryan T. , Loftus, Edward V , Edakkanambeth Varayil, Jithinraj

Mayo Clinic

Crohn's & Colitis 360 | October 14, 2020 | Volume: 2 | Issue: 4 | Pages: No page available

10.1093/crocol/otaa083 | PMID 34142084 Get It

Abstract Background We sought to estimate the incidence of home parenteral nutrition (HPN) use in a population-based cohort of patients with Crohn disease (CD), and to assess clinical outcomes and complications associated with HPN. Methods We used the Rochester Epidemiology Project (REP) to identify residents of Olmsted County, who were diagnosed with CD between 1970 and 2011, and required HPN. Results Fourteen out of 429 patients (3.3%) with CD received HPN (86% female). Eleven patients (79%) had moderate–severe CD and 12 patients (86%) had fistulizing disease. Thirteen patients (93%) underwent surgery, primarily due to obstruction. Among CD incidence cases, the cumulative incidence of HPN from the date of CD diagnosis was 0% at 1 year, 0.5% at 5 years, 0.8% at 10 years, and 2.4% at 20 years. Indications for HPN included short bowel syndrome in 64%, malnutrition in 29%, and bowel rest in 21%. The median duration of HPN was 2.5 years. There was an average weight gain of 1.2 kg at 6 months, an average weight loss of 1.4 kg at 1 year, and a further weight loss of 2.2 kg at 2 years from the start of HPN. Patients were hospitalized a mean of 5 times after the start of HPN, mainly due to catheter-related bloodstream infections and thrombosis. Conclusions Less than 4% of patients with CD need HPN. Most have moderate to severe disease with short bowel syndrome or malnutrition. Possible reasons for the patients’ weight loss could be noncompliance, and increased metabolic needs because of active disease.
Reducing burdens of site feasibility assessments for conducting clinical trials.
Kurbegov, Dax, Hurley, Patricia A. , Nowakowski, Grzegorz S. , Kim, Edward S. , Hurley, Patricia , Waterhouse, David

Mayo Clinic

Journal of Clinical Oncology | October 8, 2020 | Volume: 38 | Issue: 29_suppl | Pages: 300-300

10.1200/jco.2020.38.29_suppl.300 Get It

300 Background: Current methods to assess site feasibility for industry-funded clinical trials are onerous and delay patient access to novel treatment options and high-quality clinical trials. Industry sponsors and contract research organizations (CROs) often probe for unnecessary and/or duplicative information. These burdens prolong trial start-up times and are a barrier to site participation in oncology trials. The American Society of Clinical Oncology (ASCO) Research Community Forum convened a task force to identify ways to improve the site feasibility assessment process. Methods: Data were collected in 3 steps: 1) survey to assess site burdens, 2) collation of sample feasibility questionnaires (FQs), and 3) stakeholder meeting to discuss potential solutions. The task force then developed recommendations for process improvements and obtained stakeholder feedback through a survey. Results: 113 oncology practices (66 community, 47 academic) reported completing a median 5 FQs and 2 pre-study site visits (PSSVs) per month. FQs took a median 2 hours to complete whereas PSSVs took a median 4 hours to complete. Most considered FQ (81%) and PSSV (91%) content redundant to information previously provided, and FQs similar between different sponsors (86%). The median time from first contact to first patient enrolled was 6 months. The 40 respondents to the stakeholder survey represented 19 academic- and 9 community-based sites, 8 industry sponsors, and 4 CROs. Most preferred a model with a short FQ plus a PSSV when there was not a prior relationship. If there was a prior relationship, either a PSSV or teleconference was preferred. All stakeholders identified time savings, expedited start-up, fewer staff resources, and cost savings as the greatest benefits. The greatest barriers to adoption were buy-in from sponsors and CROs, and insufficient information about site capabilities. Conclusions: Site feasibility assessments for industry-sponsored trials are important to ensure patient safety and access to high quality clinical trials. However, current methods are inefficient and time and resource intensive. This initiative provided insights about challenges for sites and the viability of a fundamental change to site feasibility assessments. ASCO recommendations are forthcoming on improving processes, standardizing and minimizing questions, and using portals that are effective across all trials and clinical research scenarios.
Cystatin C regulates the cytotoxicity of infection‐induced endothelial‐derived β‐amyloid
Balczon, Ron , Morrow, K. Adam, Leavesley, Silas J. , Francis, C. Michael , Stevens, Trevor C., Agwaramgbo, Ezinne, Stevens, R.P. , Langham, Geri, Voth, S.B. , Cioffi, Eugene A., Weintraub, Susan, Stevens, Troy , Leavesley, Silas , Williams, Christopher, Weintraub, Susan T.

Mayo Clinic

FEBS Open Bio | October 8, 2020 | Volume: 10 | Issue: 11 | Pages: 2464-2477

10.1002/2211-5463.12997 | PMID 33030263 Get It

Infection of rat pulmonary microvascular endothelial cells with the bacterium Pseudomonas aeruginosa induces the production and release of cytotoxic oligomeric tau and beta amyloid (Aβ). Here, we characterized these cytotoxic amyloids. Cytotoxic behavior and oligomeric tau were partially resistant to digestion with proteinase K, but cytotoxicity was abolished by various denaturants including phenol, diethylpyrocarbonate (DEPC), and 1,1,1,3,3,3‐hexafluoro‐2‐isopropanol (HFIP). Ultracentrifugation for 8 h at 150 000 g was required to remove cytotoxic activity from the supernatant. Ultracentrifugation, DEPC treatment, and immunodepletion using antibodies against Aβ also demonstrated that cytoprotective protein(s) are released from endothelial cells during P. aeruginosa infection. Mass spectrometry of endothelial cell culture media following P. aeruginosa infection allowed identification of multiple potential secreted modulators of Aβ, including cystatin C, gelsolin, and ApoJ/clusterin. Immunodepletion, co‐immunoprecipitation, and ultracentrifugation determined that the cytoprotective factor released during infection of endothelial cells by P. aeruginosa is cystatin C, which appears to be in a complex with Aβ. Cytoprotective cystatin C may provide a novel therapeutic avenue for protection against the long‐term consequences of infection with P. aeruginosa.
An international multidisciplinary consensus statement on the prevention of opioid‐related harm in adult surgical patients
Levy, Nicholas , Quinlan, Jane , El‐Boghdadly, Kariem , Fawcett, William , Agarwal, Vandana , Bastable, Ruth, Cox, Felicia , Boer, Hans D. de , Dowdy, Sean C. , Hattingh, Kim, Knaggs, Roger , Mariano, Edward R. , Scott, Michael J. , Lobo, Dileep N. , Macintyre, Pamela E. , Levy, N , Quinlan, J , El-Boghdadly, K , Fawcett, W J , Agarwal, V , Cox, F J , de Boer, H D , Knaggs, R D , Mariano, Edward R , Scott, M J , Lobo, D N , Macintyre, P E , Pelosi, Paolo

Mayo Clinic

Anaesthesia | October 7, 2020 | Volume: 76 | Issue: 4 | Pages: 520-536

10.1111/anae.15262 | PMID 33027841 Get It

Summary This international multidisciplinary consensus statement was developed to provide balanced guidance on the safe peri‐operative use of opioids in adults. An international panel of healthcare professionals evaluated the literature relating to postoperative opioid‐related harm, including persistent postoperative opioid use; opioid‐induced ventilatory impairment; non‐medical opioid use; opioid diversion and dependence; and driving under the influence of prescription opioids. Recommended strategies to reduce harm include pre‐operative assessment of the risk of persistent postoperative opioid use; use of an assessment of patient function rather than unidimensional pain scores alone to guide adequacy of analgesia; avoidance of long‐acting (modified‐release and transdermal patches) opioid formulations and combination analgesics; limiting the number of tablets prescribed at discharge; providing deprescribing advice; avoidance of automatic prescription refills; safe disposal of unused medicines; reducing the risk of opioid diversion; and better education of healthcare professionals, patients and carers. This consensus statement provides a framework for better prescribing practices that could help reduce the risk of postoperative opioid‐related harm in adults.
Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS
Kim, Soyoung , Hu, Zhen‐Huan , Aljurf, Mahmoud , Beitinjaneh, Amer , Cahn, Jean‐Yves, Černý, Jan , Copelan, Edward A. , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hamilton, Betty K. , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Kamble, Rammurti T., Kindwall‐Keller, Tamila L. , Litzow, Mark R. , Rizzieri, David A. , Seo, Sachiko , Solh, Melhem , Verdonck, Leo F. , Wirk, Baldeep , Woolfrey, Ann E. , Alyea, Edwin P. , Sobecks, Ronald , Scott, Bart L. , Nakamura, Ryotaro , Saber, Wael , Hashmi, Shahrukh, Gadalla, Shahinaz M , Kim, Soyoung , Gupta, Vikas , Liu, Ying , Bacher, Ulrike , Cahn, Jean‐Yves , Gale, Robert Peter , George, Biju , Gerds, Aaron T. , Gergis, Usama , Lazarus, Hillard M. , Liesveld, Jane L. , Maziarz, Richard Thomas , Nishihori, Taiga , Olsson, Richard F. , Savani, Bipin N. , Szer, Jeff , Yared, Jean A. , Popat, Uday R

Mayo Clinic

Blood Advances | October 2, 2020 | Volume: 4 | Issue: 19 | Pages: 4748-4757

10.1182/bloodadvances.2020002621 | PMID 33007075 Get It

Abstract Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1− myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation–based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.
Effects of intraoperative liposomal bupivacaine on pain control and opioid use after pediatric Chiari I malformation surgery: an initial experience
Lu, Victor M. , Haile, Dawit T. , Ahn, Edward S. , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 2, 2020 | Volume: 27 | Issue: 1 | Pages: 9-15

10.3171/2020.6.peds20370 | PMID 33007744 Get It

OBJECTIVE Pediatric Chiari I malformation decompression is a common neurosurgical procedure. Liposomal bupivacaine (LB) is a novel formulation that can have an impact on postoperative recovery for particular procedures, but its potential role in pediatric neurosurgery is largely unexplored. The authors sought to describe and assess their initial experience with LB in pediatric Chiari I malformation decompression to better define its potential role as an analgesic agent in a procedure for which the postoperative course is often remarkably painful. METHODS A retrospective review of all pediatric Chiari procedures performed at the authors’ institution between 2018 and 2020 was conducted. Patients were divided into those who were treated with a single intraoperative dose of LB (LB group) and those who were not (control group). Comparisons of total opioid use and pain control were made using chi-square and Wilcoxon rank-sum tests. RESULTS A total of 18 patients were identified, 9 (50%) in the LB group and 9 (50%) in the control group. Overall, there were 13 (72%) female and 5 (28%) male patients with a mean age of 15.9 years. No surgical complications were observed over a mean length of stay of 2.7 days. Within the first 24 hours after surgery, the LB group had significantly lower total opioid use than the control group (17.5 vs 47.9 morphine milligram equivalents, respectively; p = 0.03) as well as lower mean pain scores reported by patients using a 10-point visual analog scale (3.6 vs 5.5 for the LB vs control groups, p = 0.04). However, from the first 24 postoperative hours to discharge, total opioid use (p = 0.51) and mean pain scores (p = 0.09) were statistically comparable between the two groups. There were 2/9 (22%) LB patients versus 0/9 (0%) control patients who did not require opioid analgesia at any point during hospitalization. CONCLUSIONS The use of a single intraoperative dose of LB in pediatric Chiari I malformation surgery appears to be safe and has the potential to reduce pain scores and opioid use when administered during the first 24 postoperative hours. From that time period to discharge, however, there may be no significant difference in total opioid use or pain scores.
Diagnosis and Treatment of Femoral Head Osteonecrosis: A Protocol for Development of Evidence Based Clinical Practice Guidelines
Cheng, Edward Y. , Mont, Michael A. , Cui, Quanjun , Salem, Hytham S. , Bakker, Caitlin , Sugano, Nobuhiko , Goodman, Stuart B. , Sierra, Rafael J.

Mayo Clinic

No container title available | October 1, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-77450/v1 Get It

Abstract Background: There are many treatment options for patients who have osteonecrosis of the femoral head (ONFH) and management strategies vary widely both among and within individual countries. Although many researchers have attempted to elucidate the optimal strategies for managing this disease, the lack of large-scale randomized control trials and the lack of agreement on disease staging have curtailed the development of clear-cut guidelines.Methods: The Association Research Circulation Osseous (ARCO) group sought to address three questions for the management of patients who have ONFH: (1) What imaging studies are most sensitive and specific for the diagnostic evaluation of patients who have ONFH?; (2)What is the best treatment strategy for preventing disease progression in patients who have pre-collapse lesions?; and (3) What is the best treatment strategy for patients who have post-collapse disease? The PICO (Patient, Intervention, Comparison, and Outcome) format was used to formulate the search strategy for each research question. A systematic review will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. ARCO participants have been allocated to three groups, each representing one of the PICO questions. After qualitative and quantitative analysis of the data extracted from studies pertaining to each of the three research questions, a set of evidence-based clinical practice guidelines will be proposed for the management of patients who have ONFH. Discussion: It is not always clear which treatment method is optimal for the management of ONFH. Thus, many surgeons have developed and performed various procedures based on various patient-specific factors. As there is no consensus on the optimal treatment for various stages of disease, it was clear that developing evidence-based clinical practice guidelines would provide more structure and uniformity to management of these patients. Therefore, the results of this systematic review will lead to the development guidelines that may improve patient-care strategies and result in better outcomes for patients who have ONFH.Systematic Review Registration: Registration with PROSPERO has been submitted and is pending.
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors
Eads, Jennifer R. , Reidy‐Lagunes, Diane , Chan, Jennifer A. , Anthony, Lowell , Hálfdánarson, Þorvarður R. , Naraev, Boris G., Wolin, Edward M. , Halperin, Daniel M. , Pommier, Rodney F. , Zacks, Jerome, Morse, Michael A. , Metz, David C. , Collaborative, from the Carcinoid Syndrome Control, Halfdanarson, Thorvardur R , Soares, Heloisa P. , Li, Daneng , Collaborative, from the Carcinoid Syndrome Control

Mayo Clinic

Pancreas | September 29, 2020 | Volume: 49 | Issue: 9 | Pages: 1123-1130

10.1097/mpa.0000000000001658 | PMID 32991344 Get It

Abstract Patients with neuroendocrine tumors (NETs) and carcinoid syndrome experience diarrhea that can have a debilitating effect on quality of life. Diarrhea also may develop in response to other hormonal syndromes associated with NETs, surgical complications, medical comorbidities, medications, or food sensitivities. Limited guidance on the practical approach to the differential diagnosis of diarrhea in these patients can lead to delays in appropriate treatment. This clinical review and commentary underscore the complexity in identifying the etiology of diarrhea in patients with NETs. Based on our collective experience and expertise, we offer a practical algorithm to guide medical oncologists and other care providers to expedite effective management of diarrhea and related symptoms in patients with NETs.